PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for November 14, 2003 Subscribe to this News Feed    
 

Reduce Drug Costs: One Hospital Expects $170,000 Savings from SQ Erythropoietic Drug Switch

When quality and cost are in constant competition, as they are in health care, new products or procedures that are lower cost and also therapeutically successful can be valuable discoveries for both the patient and the facility. Successful performance improvement measures and discoveries that have helped hospitals meet these industry challenges are posted on The Healthcare Management Councils KnowledgeWeb (http://www.HMC-Benchmarks.com/hospital/tools_kw.shtml) and shared with healthcare professionals around the country.

Needham, MA (PRWEB) November 14, 2003 -- High drug prices make it difficult for hospitals today to contain pharmaceutical costs without compromising the quality of patient care. John Solomon, Director of Pharmacy Services at Westmoreland Health System (WHS) in Greensburg, PA, was confronted with this problem when he discovered through The Healthcare Management Council Inc. benchmark (http://www.HMC-Benchmarks.com/hospital/) that his facility was spending more than others on pharmaceuticals.

Solomon and his team began testing the effectiveness of new, more cost efficient drugs and found Amgens new SQ erythropoietic drug, Aranesp, to be one of those rare innovations in pharmacy that reduces costs, while maintaining quality performance.

Therapeutically, Aranesp has performed successfully at WHS. The side effects have been favorable and there have been no significant changes in patient outcomes. Financially, Solomon predicts that using Aranesp will result in a $170,000 savings for the health system this year.

Aranesp has been developed as a longer-acting drug relative to Amgens current product, Epogen, or Johnson & Johnsons Procrit. The new drug can be given as little as once every three weeks, compared to the previously existing drugs, which are used from once weekly up to three times weekly. The switch to Aranesp results in fewer doses per patient per treatment cycle and has led to a 20-40% decrease in cost per patient at WHS.

Solomon and the staff at WHS have found that their patients respond best to one injection per week.

This idea is part of HMCs collection of Successes and Good Ideas," articles highlighting successful performance improvement measures in health care. For more information on these articles and other HMC hospital networking events visit http://www.HMC-Benchmarks.com/hospital/ccs.shtml.

Contact: Shelley Burns (SHBurns@HMCOnline.net)
The Healthcare Management Council, Inc.
Area: Hospital Performance Improvement
Web site: http://www.HMC-Benchmarks.com
Phone: (262) 242-9471

Other Releases by this Member
OPTIONS
Printer Friendly Version
Email this story to a colleague
CONTACT INFORMATION
Shelley Burns
The Healthcare Management Council, Inc.
262-242-9471
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.